Author of the value investing newsletter detailing the formation of the "Punch Card Portfolio" (http://valueinvestorcanada.blogspot.com/). Devon Shire is an accountant and an investor with 15 years experience managing a private portfolio. Devon Shire's preferred portfolio management style is a concentrated approach, investing only when finding opportunities that offer a sufficient discount to the intrinsic value of a business. Devon can be contacted at email@example.com.
I Have over 20 years experience in trading stock, options commodities and bonds.
I have a special interest in undervalued and/or Biotech stocks.
I intend to write about the Bio-tech sector.
I specialize in rooting out corporate fraud and financial shenanigans in small and micro cap stocks. I am here to bring true institutional quality research on both longs and shorts to the seekingalpha community. If you have any particular company or stock you believe is committing fraud or doing anything illegal and would like to share this information with us we can assure your identity will always be kept 100% anonymous. We will respect your privacy without question and treat your sensitive information with the proper respect.
Cloud and Wind Global Capital Management is an indep- endent alternative investment management firm. The firm currently manages a global fund of hedge funds for instit- utional investors and high-net-worth individuals.
I am currently an individual investor with focus on event-driven trading and long-short opportunities. I graduated Emory University in 2009 and am also a finance Phd dropout from UCLA Anderson. I could be reached at firstname.lastname@example.org
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com, and on most days is still ranked in the top 5%. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
Investment professional and CFA charterholder. I write on Seeking Alpha as a personal hobby and to elicit feedback on specific ideas and topics, help organize my thinking, and connect with intelligent people.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
Prescience Point's founders have over 25 years of combined Wall Street experience, and a significant track-record of successful short recommendations.
The sole focus of our company is to conduct comprehensive fundamental research, and uncover companies that are engaging in fraudulent or misleading business practices. We partner with leading hedge funds, private investigators, accountants, lawyers and industry experts to conduct our research process. We take an activist role to communicate our findings to regulators, shareholders, and other public constituents.
Our firm was founded on the belief that investors deserve full and complete honesty, transparency and accountability from corporations they invest with. We set high expectations and standards for our research process and opinions, and strive to achieve the respect from our readers for our integrity, intellectual honesty, analytical rigor, and accuracy of our conclusions.
Prescience Investment Group is a research-driven, performance-oriented investment firm. Prescience manages a private investment fund on behalf of its clients and principals with the objective of generating superior absolute investment returns over the full cycle of market and economic conditions.
We specialize in extensive, investigative research on difficult-to-analyze or obscure public companies in order to develop unique insights and identify singular investment opportunities. We seek out abnormally large disparities between what businesses are intrinsically worth and what they sell for and invest accordingly, long and short.
Ivy League grad, summa cum laude, 4.0 in Economics, Columbia J.D., 20+ years experience identifying early trends and themes b4 the Wall St herd. In search of undervalued, underfollowed, explosive growth opportunities, principally in, but not limited to, the biotech sector.
Daniel B. Ravicher is a registered patent attorney who frequently consults with investment banks, hedge funds, and individual investors on legal issues that may materially affect the value of publicly traded companies. In addition to private consulting, Mr. Ravicher also regularly publishes articles covering such issues. He is not an investment adviser and the opinions expressed are not legal, financial or any other kind of advice.
In his legal practice, Mr. Ravicher provides transaction and litigation legal services to clients with respect to a wide range of technologies, including pharmaceuticals, biotechnology, software, the Internet, mobile devices, mechanical devices, consumer products and business methods. He represented the successful plaintiffs in the Supreme Court case invalidating patents on human genes and has twice testified before Congress on the topic of patent reform. Repeatedly named one of 'The 50 Most Influential People in IP' by Managing Intellectual Property and named Appellate Lawyer of the Week by the National Law Journal, Mr. Ravicher has appeared as a guest on national television, been quoted in articles by the Wall Street Journal, Bloomberg, the New York Times, the Financial Times and other publications, and spoken at dozens of national and international conferences on issues relating to patent and technology law.
Mr. Ravicher received his law degree from the University of Virginia School of Law, where he was the Franklin O'Blechman Scholar of his class, a Mortimer Caplin Public Service Award recipient and an Editor of the Virginia Journal of Law and Technology, and his bachelors degree in materials science magna cum laude with University Honors from the University of South Florida. He is admitted to the United States Supreme Court, the Courts of Appeals for the Federal, 2nd and 11th Circuits, the District Courts for the Southern and Eastern Districts of New York and the Southern and Middle Districts of Florida, the States of New York and Florida, and the United States Patent and Trademark Office.
Sharesleuth.com is an investigative business reporting site backed by entrepreneur Mark Cuban. Sharesleuth seeks to expose companies and individuals engaged in securities fraud and other activities that tend to deceive investors. Chris Carey, editor of Sharesleuth, previously was an award-winning business reporter at the St. Louis Post-Disptach, the Indianapolis Star, and the Orlando Sentinel. He began his career at the Messenger-Inquirer in Owensboro, Ky. He graduated from Indiana University with a double major in journalism and economics.
I am a research analyst for a long/short value-oriented hedge fund. Most of my attention is focused on the tech, telecom and media sectors although I occasionally look for value (or its opposite) in other areas.
Note that I take long and short positions in the stocks I discuss on Seeking Alpha. Although I disclose my positions at the time of publication, these may change at any time without notice. Nothing I write should be construed as investment advice or a recommendation to buy or sell specific securities. Please do your own research and/or consult with a financial adviser. While everything I write is factually correct to the best of my knowledge, I encourage you to notify me in the comments section when you think I may be in error.
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
I've been contributing to SA since 2011, with a break to join the PRO editorial team from 2013-2015. I got my Series 7 and 63 back in 2000, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail brokerage in NYC.
Apsara Biotech Research provides in-depth research on publicly traded stocks in the biotechnology sector. We pride ourselves on conducting high quality research for our clients and the public markets. Apsara is not affiliated with a broker-dealer and does not underwrite public offerings or provide investment banking services to the companies that it researches. Therefore, the research coverage provided in our reports are not influenced by the prospect of future investment banking and underwriting fee revenue.
Instead, Apsara and its contributors hold long and short positions in the stocks that we write about. Our research commentary is supported by our genuine opinions about the securities covered, rather than a motivation to derive future fee revenue from the subject companies.
We hope that you find our approach to biotechnology sector research refreshing, original and accurate.
Our research director is Yang Yu and can be reached at email@example.com
Todd Sullivan is a Massachusetts-based value investor and Co-Founder and General Partner in Rand Strategic Partners. He looks for investments he believes are selling for a discount to their intrinsic value given their current situation and future prospects. He holds them until that value is realized or the fundamentals change in a way that no longer support his original thesis. His blog features his various ideas and general commentary and he updates readers on their progress in a timely fashion. His commentary has been seen in the online versions of the Wall St. Journal, New York Times, CNN Money, Business Week, Crain's NY and others. He has also appeared on Fox Business News and is a RealMoney.com contributor. Visit his sites: ValuePlays (http://valueplays.net/) , Rand Strategic Partners (http://randstrategicpartners.com)
MHAF (Special Situations in Healthcare and Technology)
Fund concentrated in Special Situation growth stocks. We are proponents of only investing in ideas which we can evaluate ourselves (most sell-side research ideas are entirely biased due to investment banking relationships and are therefore almost always flawed).
Our ideas are our own.
Please do your own research as we do not make investment recommendations.
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.
My investment philosophy is to employ bottom-up fundamental-driven equity analysis as a sustainable long-term path to alpha generation. I have been investing in technology stocks since 1997 and am particularly passionate about the Internet sector and how it's fundamentally re-shaping the most important fabrics of society.
I hold a Bachelors of Mathematics in Computer Science from the University of Waterloo and an MBA in Finance and Entrepreneurship from the Wharton School.
I'm currently seeking a job as a long/short equity analyst. You may reach me at firstname.lastname@example.org with any job opportunities or any other questions/comments.